Trials for new Alzheimer’s drugs have been failing a lot, lately. But it may be premature to abandon these drugs altogether.
Academic rigour, journalistic flair
Articles on Drug development
Displaying 61 - 80 of 107 articles
Alzheimer’s drug development tends to focus on protein aggregates in the brain. Perhaps that’s why they’ve all failed.
Researchers who’ve created a kidney-on-a-chip explain why these kinds of devices are an improvement over traditional ways to test new drugs.
Thousands of animals are used for heart drug tests each year – but research shows that in silico developments are more accurate.
Medicinal chemists are tweaking a natural molecule that can be a deadly poison – a modified version might work as a nonhormonal male contraceptive.
Only around 10% of new drugs in development make it onto the market. A drug needs to go through animal trials, and then four phases of human trials to be deemed suitable for use in patients.
A randomised controlled trial is the best way to compare a new treatment with the standard treatment. And randomising trial participants is a core feature of the experiment.
3D bioprinting of living cells and materials may contribute to faster and cheaper ways to create effective new drugs - and even reduce animal testing.
Researchers are finding medical uses for some molecules in certain street drugs, but it’s important to call the drugs by their real names. Here’s why that’s important.
Australia has never been short of inventors, scientists aren’t always at home in the ruthless world of commerce. But if they can be given a helping hand, it could help the entire economy.
News reports this week hailing a breakthrough in Alzheimer’s research, saying a vaccine for the disease is a few years away, have raised hopes for many. But let’s take a step back from the headlines.
Human guinea pigs? On the occasion of Rennes drama, an explanation of what the drug trials in France and how they are controlled.
Many venoms contain bioactive components that are so stable to the body’s enzymes and selective of their biological target that they’re increasingly being used as novel research tools.
Thalidomide was developed in an era of widespread enthusiasm – but little critical attention – for pharmaceutical therapies.
Thalidomide was marketed as a safe, sleep-inducing drug, but when taken during pregnancy it could cause severe birth defects.
Thalidomide caused thousands of spontaneous abortions and left more than 10,000 children severely disabled. What guarantee is there that the same thing can’t occur again today?
This project offers the tantalising possibility that plants containing drugs, such as agents to treat HIV, could be farmed on a small scale at low cost by communities that need them most.
News that a leading manufacturer will cease making a well-known antivenom is not actually new.
A so-called “organ-on-chip” device could speed up the way drugs are developed. And it’s just been named the London Design Museum’s design of the year.
You may not have heard of the protein lubricin, but it’s what keeps your body moving. And now it’s being used to treat disease and produce new therapeutics.
Job Board
-
Project Offier - Diversity & Inclusion
-
Senior Lecturer - Earth System Science
-
Sydney Horizon Educators (Identified)
-
Deputy Social Media Producer
-
Associate Professor, Occupational Therapy
Top contributors
-
Prof. Institute for Molecular Bioscience, The University of Queensland
-
Assistant Professor of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus
-
Associate Professor of History, University of Wollongong
-
Biostatistician, The University of Melbourne
-
Professor of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
-
Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Professor of Neuroscience, Lancaster University
-
Professor, UNSW Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Biostatistics, Murdoch Children's Research Institute
-
Director of Natural Product Discovery Core; Assistant Professor of Medicinal Chemistry, University of Michigan
-
Molecular and Clinical Pharmacology, University of Liverpool
-
Researcher, L’Université d’Ottawa/University of Ottawa
-
Executive General Manager Commercialisation and Research Contracts, Baker Heart and Diabetes Institute
